Proteinuria
Conditions
Interventions
Atorvastatin High capacity group
Atorvastatin normal capacity group
Rosuvastatin group
Sponsors
Aichi welfare agricultural cooperative association Anjo Kosei Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: the protein in urine / creatinine ratio above 150mg. Three-month or more administration of the angiotensin converting enzyme inhibitor or angiotensin 2 receptor inhibitor. the patient judged that the aggressive lipid fall treatment are required.
Exclusion criteria
Exclusion criteria: The patient who caused acute coronary syndrome within six months. The patient of an inflammatory disorder, infection, and a malignant tumor. The patient who has an anamnesis of hypersensitivity to atorvastatin and/or rosuvastatin. A pregnant woman or the woman that may have become pregnant, and a nursing mother. A patient with critical impaired liver function and renal dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the protein in urine / creatinine ratio after 52 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of the protein in urine / creatinine ratio after 26 weeks Change of the albumin in urine / creatinine ratio after 26 weeks and 52 weeks Lipid rate of change after 26 weeks and 52 weeks Change of eGFR after 26 weeks and 52 weeks | — |
Countries
Japan
Contacts
Public ContactMasanori Ito
Aichi welfare agricultural cooperative association Anjo Kosei Hospital Division of Cardiology, Department of Internal Medicine
Outcome results
None listed